Atrial Fibrillation Following Intravenous Zolendronic Acid for Osteoporosis

Konsta, Maria; Bournia, Vasiliki-Kalliopi; Dania, Vasiliki; Iliopoulos, Alexios

doi:10.1097/rhu.0000000000000114

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initial suggestion of association between bisphosphonate therapy and AF was mainly derived from serious adverse event reports (SAE) of HORIZON-PFT [2]. Later retrospective studies and meta-analyses failed to reach a consistent conclusion regarding the proposed association between bisphosphonate therapy and AF [3][4][5][6]. However, data gathered from prospective studies which directly evaluate the effects of biphosphonates on cardiac arrhythmias are still lacking.…”

Section: Discussionmentioning

confidence: 95%

“…Most of the AF events occurred more than 30 days after ZA infusion [2]. Subsequent reports raised further concern for a possible class effect of biphosphonates; however, studies failed to demonstrate a consistent association between biphosphonate therapy and risk for development of AF [3,4].…”

Section: Introductionmentioning

confidence: 94%

“…In 2008, the US and Food and Drug Administration (FDA) found no significant association between biphosphonate use and risk of AF [4]. However, many other studies and metaanalyses published after the report of the FDA reported significant association between oral and intravenous biphosphonate use and risk for development of AF [5,6].…”

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis

et al. 2016

View full text Add to dashboard Cite

ZA infusion did not affect P wave dispersion both at the immediate post-infusion period and 1 month after infusion. QT values were significantly increased early after ZA infusion; however, there were no significant differences in parameters reflecting disparity of ventricular recovery times and transmural dispersion of ventricular repolarization. Based on these observations, it may be suggested that ZA infusion did not have any short- or long-term effect on any parameter that might be associated with the tendency for atrial fibrillation or ventricular arrhythmias.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Реже встречается ЛИФП на фоне приема бисфосфонатов (в 2,2% случаев на фоне лечения золедроновой кислотой) [217][218][219][220][221][222]. Для ряда групп ЛС (ЛС, влияющие на мочеполовую систему [203][204][205][206][207], иммунодепрессанты [208][209][210][211][212][213][214][215], анестетики [216] и другие [223][224][225][226][227][228]) описаны лишь отдельные клинические случаи возникновения ЛИФП/ТП.…”

Section: Drug-induced Atrial Fibrillation лекарственно-индуцированная...unclassified

Drug-Induced Atrial Fibrillation / Atrial Flutter

Остроумова

Chernyaeva

Кочетков

et al. 2022

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Drug-induced atrial fibrillation / flutter (DIAF) is a serious and potentially life-threatening complication of pharmacotherapy. Purpose of the work: systematization and analysis of scientific literature data on drugs, the use of which can cause the development of DIAF, as well as on epidemiology, pathophysiological mechanisms, risk factors, clinical picture, diagnosis and differential diagnosis, treatment and prevention of DIAF. Analysis of the literature has shown that many groups of drugs can cause the development of DIAF, with a greater frequency while taking anticancer drugs, drugs for the treatment of the cardiovascular, bronchopulmonary and central nervous systems. The mechanisms and main risk factors for the development of DIAF have not been finally established and are known only for certain drugs, therefore, this section requires further study. The main symptoms of DIAF are due to the severity of tachycardia and their influence on the parameters of central hemodynamics. For diagnosis, it is necessary to conduct an electrocardiogram (ECG) and Holter monitoring of an ECG and echocardiography. Differential diagnosis should be made with AF, which may be caused by other causes, as well as other rhythm and conduction disturbances. Successful treatment of DIAF is based on the principle of rapid recognition and immediate discontinuation of drugs (if possible), the use of which potentially caused the development of adverse drug reactions (ADR). The choice of management strategy: heart rate control or rhythm control, as well as the method of achievement (medication or non-medication), depends on the specific clinical situation. For the prevention of DIAF, it is necessary to instruct patients about possible symptoms and recommend self-monitoring of the pulse. It is important for practitioners to be wary of the risk of DIAF due to the variety of drugs that can potentially cause this ADR.

show abstract

Zoledronic acid

2015

Reactions Weekly

View full text Add to dashboard Cite

Atrial Fibrillation Following Intravenous Zolendronic Acid for Osteoporosis

Cited by 3 publications

References 12 publications

Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis

Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis

Drug-Induced Atrial Fibrillation / Atrial Flutter

Zoledronic acid

Contact Info

Product

Resources

About